CD38 expression
CD38 is on almost every myeloma cell, so daratumumab and isatuximab are given without testing for it. The stain matters afterwards: CD38 falls after treatment and can confuse flow cytometry and blood typing.
Overview
Daratumumab and isatuximab are CD38-directed antibodies labelled for multiple myeloma by line of therapy, not by CD38 level; every label describes the antigen only in the mechanism section. CD38 expression is near-universal on plasma cells and drops for months after anti-CD38 therapy, which is why laboratories use alternative gating in flow cytometry and why the drugs interfere with indirect antiglobulin tests.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CD38 is a myeloma surface enzyme and the target of daratumumab, which is now given as a quick under-the-skin injection.
You will not usually be tested for CD38 before daratumumab or isatuximab; the antigen is present on virtually all myeloma cells. Tell any hospital laboratory you are on an anti-CD38 antibody, because it interferes with blood-matching tests for transfusion.
Written only from the label or guideline text cited on this page. Not medical advice; your own report and the reading your team gives it come first.
The label names the antigen in the drug's description but does not require it to be measured before treatment; no approval threshold exists for this readout.
“DARZALEX is a CD38-directed cytolytic antibody”
DARZALEX prescribing information (DailyMed)No approval uses this readout as a threshold.
Matched on the name and aliases of the readout in the title, setting and summary of each trial; a match is a mention, not proof the readout was an entry criterion.
- NCT03319667 · 2024IMROZ
- NCT02541383 · 2019CASSIOPEIA
- NCT07258511A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- NCT07518186A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- NCT06208150A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez
- NCT05572515A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With
- NCT07312188A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
- NCT07266441A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
- NCT02963493A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- NCT06669247A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Mult
- NCT07523555Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
- NCT06152575MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other
- NCT05565807Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
Similar pages
not linked directly; found by shared links- BiomarkerFcRH5 expression
Shares GPRC5D expression, BCMA expression, Relapsed or refractory multiple myeloma, Multiple myeloma and the tags biomarker, surface-antigen, no-threshold.
- BiomarkerB7-H3 (CD276) expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerCEACAM5 expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerDLL3 expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerHER3 expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerNectin-4 expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerTissue factor expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerTROP2 expression
Shares the tags biomarker, surface-antigen, no-threshold.